(Q28254804)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4

Seth M Steinberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

10

Raffit Hassan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

5

Ira Pastan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

6

Masanori Onda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Elad Sharon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jingli Zhang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Kevin Hollevoet

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jochen Gaedcke

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

B Michael Ghadimi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Thomas Ried

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

English

0 references

publication date

1 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

Clinical Chemistry and Laboratory Medicine

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

721-725

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Outcomes in unresectable and locally advanced resected cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Mesothelin variant 1 is released from tumor cells as a diagnostic marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

MESOMARK: a potential test for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Mesothelin-family proteins and diagnosis of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.816

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

21 January 2018

1 reference

12 December 2020

Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis

1 reference

12 December 2020

Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma

1 reference

12 December 2020

Carbohydrate markers of pancreatic cancer

1 reference

12 December 2020

Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma

1 reference

12 December 2020

The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.

1 reference

12 December 2020

Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1515/CCLM.2011.816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22149739%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

22149739

1 reference